Literature DB >> 25767292

Iron homeostasis and pulmonary hypertension: iron deficiency leads to pulmonary vascular remodeling in the rat.

Emanuele Cotroneo1, Ali Ashek1, Lei Wang1, John Wharton1, Olivier Dubois1, Sophie Bozorgi1, Mark Busbridge1, Kambiz N Alavian1, Martin R Wilkins1, Lan Zhao2.   

Abstract

RATIONALE: Iron deficiency without anemia is prevalent in patients with idiopathic pulmonary arterial hypertension and associated with reduced exercise capacity and survival.
OBJECTIVES: We hypothesized that iron deficiency is involved in the pathogenesis of pulmonary hypertension and iron replacement is a possible therapeutic strategy. METHODS AND
RESULTS: Rats were fed an iron-deficient diet (IDD, 7 mg/kg) and investigated for 4 weeks. Iron deficiency was evident from depleted iron stores (decreased liver, serum iron, and ferritin), reduced erythropoiesis, and significantly decreased transferrin saturation and lung iron stores after 2 weeks IDD. IDD rats exhibited profound pulmonary vascular remodeling with prominent muscularization, medial hypertrophy, and perivascular inflammatory cell infiltration, associated with raised pulmonary artery pressure and right ventricular hypertrophy. IDD rat lungs demonstrated increased expression of hypoxia-induced factor-1α and hypoxia-induced factor-2α, nuclear factor of activated T cells and survivin, and signal transducers and activators of transcription-3 activation, which promote vascular cell proliferation and resistance to apoptosis. Biochemical examination showed reduced mitochondrial complex I activity and mitochondrial membrane hyperpolarization in mitochondria from IDD rat pulmonary arteries. Along with upregulation of the glucose transporter, glucose transporter 1, and glycolytic genes, hk1 and pdk1, lung fluorine-18-labeled 2-fluoro-2-deoxyglucose ligand uptake was significantly increased in IDD rats. The hemodynamic and pulmonary vascular remodeling were reversed by iron replacement (ferric carboxymaltose, 75 mg/kg) and attenuated in the presence of iron deficiency by dichloroacetate and imatinib, 2 putative treatments explored for pulmonary arterial hypertension that target aerobic glycolysis and proliferation, respectively.
CONCLUSIONS: These data suggest a major role for iron in pulmonary vascular homeostasis and support the clinical evaluation of iron replacement in patients with pulmonary hypertension.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  STAT3; glycolysis; hypertension, pulmonary; iron; vascular remodeling

Mesh:

Substances:

Year:  2015        PMID: 25767292     DOI: 10.1161/CIRCRESAHA.116.305265

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  50 in total

1.  Iron Metabolism and Vascular Remodeling: Novel Insights Provided by Transferrin-1 Receptor Depletion in Mice With Pulmonary Hypertension.

Authors:  Michael S Wolin; Dhara Patel; Raed Alhawaj; Sachin A Gupte; Dong Sun
Journal:  Am J Hypertens       Date:  2015-11-04       Impact factor: 2.689

Review 2.  New and Emerging Therapies for Pulmonary Arterial Hypertension.

Authors:  Edda Spiekerkoetter; Steven M Kawut; Vinicio A de Jesus Perez
Journal:  Annu Rev Med       Date:  2018-09-14       Impact factor: 13.739

3.  Pulmonary Arterial Hypertension Is Associated with Oxidative Stress-induced Genome Instability.

Authors:  Bennett Van Houten
Journal:  Am J Respir Crit Care Med       Date:  2015-07-15       Impact factor: 21.405

Review 4.  The Search for Disease-Modifying Therapies in Pulmonary Hypertension.

Authors:  Chen-Shan Chen Woodcock; Stephen Y Chan
Journal:  J Cardiovasc Pharmacol Ther       Date:  2019-02-17       Impact factor: 2.457

5.  BOLA (BolA Family Member 3) Deficiency Controls Endothelial Metabolism and Glycine Homeostasis in Pulmonary Hypertension.

Authors:  Qiujun Yu; Yi-Yin Tai; Ying Tang; Jingsi Zhao; Vinny Negi; Miranda K Culley; Jyotsna Pilli; Wei Sun; Karin Brugger; Johannes Mayr; Rajeev Saggar; Rajan Saggar; W Dean Wallace; David J Ross; Aaron B Waxman; Stacy G Wendell; Steven J Mullett; John Sembrat; Mauricio Rojas; Omar F Khan; James E Dahlman; Masataka Sugahara; Nobuyuki Kagiyama; Taijyu Satoh; Manling Zhang; Ning Feng; John Gorcsan; Sara O Vargas; Kathleen J Haley; Rahul Kumar; Brian B Graham; Robert Langer; Daniel G Anderson; Bing Wang; Sruti Shiva; Thomas Bertero; Stephen Y Chan
Journal:  Circulation       Date:  2019-05-07       Impact factor: 29.690

Review 6.  Integration of complex data sources to provide biologic insight into pulmonary vascular disease (2015 Grover Conference Series).

Authors:  Evan L Brittain; Stephen Y Chan
Journal:  Pulm Circ       Date:  2016-09       Impact factor: 3.017

Review 7.  Mitochondrial metabolism in pulmonary hypertension: beyond mountains there are mountains.

Authors:  Miranda K Culley; Stephen Y Chan
Journal:  J Clin Invest       Date:  2018-08-06       Impact factor: 14.808

Review 8.  Health Disparities in Patients with Pulmonary Arterial Hypertension: A Blueprint for Action. An Official American Thoracic Society Statement.

Authors:  Arunabh Talwar; Joe G N Garcia; Halley Tsai; Matthew Moreno; Tim Lahm; Roham T Zamanian; Roberto Machado; Steven M Kawut; Mona Selej; Stephen Mathai; Laura Hoyt D'Anna; Sonu Sahni; Erik J Rodriquez; Richard Channick; Karen Fagan; Michael Gray; Jessica Armstrong; Josanna Rodriguez Lopez; Vinicio de Jesus Perez
Journal:  Am J Respir Crit Care Med       Date:  2017-10-15       Impact factor: 21.405

9.  Iron is associated with the development of hypoxia-induced pulmonary vascular remodeling in mice.

Authors:  Yoshiro Naito; Manami Hosokawa; Hisashi Sawada; Makiko Oboshi; Toshihiro Iwasaku; Yoshitaka Okuhara; Akiyo Eguchi; Koichi Nishimura; Yuko Soyama; Shinichi Hirotani; Toshiaki Mano; Masaharu Ishihara; Tohru Masuyama
Journal:  Heart Vessels       Date:  2016-06-16       Impact factor: 2.037

10.  Carbonic anhydrase IX is a critical determinant of pulmonary microvascular endothelial cell pH regulation and angiogenesis during acidosis.

Authors:  Ji Young Lee; Mikhail Alexeyev; Natalya Kozhukhar; Viktoriya Pastukh; Roderica White; Troy Stevens
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-04-05       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.